Search

Your search keyword '"Lee, Mei-Hsuan"' showing total 602 results
Start Over Author "Lee, Mei-Hsuan"
602 results on '"Lee, Mei-Hsuan"'

153. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy

Author

Wang, Hung-Wei, primary, Lai, Hsueh-Chou, additional, Hu, Tsung-Hui, additional, Su, Wen-Pang, additional, Lu, Sheng-Nan, additional, Lin, Chia-Hsin, additional, Hung, Chao-Hung, additional, Chuang, Po-Heng, additional, Wang, Jing-Houng, additional, Lee, Mei-Hsuan, additional, Chen, Chien-Hung, additional, and Peng, Cheng-Yuan, additional

Published
2018
Full Text
View/download PDF

159. Mo1421 - Validation of a Clinical Scoring System to Predict Risk of Hepatocellular Carcinoma (HCC) in an Ethnically Diverse Cohort of Patients with Chronic Hepatitis C Virus (HCV) Infection

Author

Wei, Mike, primary, Le, Michael H., additional, Le, An K., additional, Trinh, Huy N., additional, Wong, Grace L., additional, Landis, Charles, additional, Zhang, Jian, additional, Nguyen, Pauline, additional, Lee, Mei-Hsuan, additional, Ji, Fanpu, additional, Lee, Dong Hyun, additional, Ogawa, Eiichi, additional, Chang, Matthew, additional, and Nguyen, Mindie H., additional

Published
2018
Full Text
View/download PDF

162. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

Author

Yang, Chih-Jen, primary, Tsai, Ming-Ju, additional, Hung, Jen-Yu, additional, Lee, Mei-Hsuan, additional, Tsai, Ying-Ming, additional, Tsai, Yu-Chen, additional, Hsu, Jui-Feng, additional, Liu, Ta-Chih, additional, Huang, Ming-Shyan, additional, and Chong, Inn-Wen, additional

Published
2017
Full Text
View/download PDF

164. A high-resolution HLAimputation system for the Taiwanese population: a study of the Taiwan Biobank

Author

Huang, Yu-Han, Khor, Seik-Soon, Zheng, Xiuwen, Chen, Hsuan-Yu, Chang, Ya-Hsuan, Chu, Hou-Wei, Wu, Pei-Ei, Lin, Yu-Ju, Liao, Shu-Fen, Shen, Chen-Yang, Tokunaga, Katsushi, and Lee, Mei-Hsuan

Abstract

An imputation algorithm for human leukocyte antigen (HLA) is helpful for exploring novel disease associations. However, population-specific HLAimputation references are essential for achieving high imputation accuracy. In this study, a subset of 1012 individuals from the Taiwan Biobank (TWB) who underwent both whole-genome SNP array and NGS-based HLAtyping were used to establish Taiwanese HLAimputation references. The HIBAG package was used to generate the imputation references for eight HLAloci at a two- and three-field resolution. Internal validation was carried out to evaluate the call threshold and accuracy for each HLAgene. HLAclass II genes found to be associated with rheumatoid arthritis (RA) were validated in this study by the imputed HLAalleles. Our Taiwanese population-specific references achieved average HLAimputation accuracies of 98.11% for two-field and 98.08% for three-field resolution. The frequency distribution of imputed HLAalleles among 23,972 TWB subjects were comparable with PCR-based HLAalleles in general Taiwanese reported in the allele frequency net database. We replicated four common HLAalleles (HLA-DRB1*03:01, DRB1*04:05, DQA1*03:03, and DQB1*04:01) significantly associated with RA. The population-specific references provide an informative tool to investigate the associations of HLAvariants and human diseases in large-scale population-based studies.

Published
2020
Full Text
View/download PDF

170. Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients

Author

Lee, Mei-Hsuan, primary, Huang, Chung-Feng, additional, Lai, Hsueh-Chou, additional, Lin, Chun-Yen, additional, Dai, Chia-Yen, additional, Liu, Chun-Jen, additional, Wang, Jing-Houng, additional, Huang, Jee-Fu, additional, Su, Wen-Pang, additional, Yang, Hung-Chih, additional, Kee, Kwong-Ming, additional, Yeh, Ming-Lun, additional, Chuang, Po-Heng, additional, Hsu, Shih-Jer, additional, Huang, Ching-I, additional, Kao, Jung-Ta, additional, Chen, Chieh-Chang, additional, Chen, Sheng-Hung, additional, Jeng, Wen-Juei, additional, Yang, Hwai-I, additional, Yuan, Yong, additional, Lu, Sheng-Nan, additional, Sheen, I-Shyan, additional, Liu, Chen-Hua, additional, Peng, Cheng-Yuan, additional, Kao, Jia-Horng, additional, Yu, Ming-Lung, additional, Chuang, Wan-Long, additional, and Chen, Chien-Jen, additional

Published
2017
Full Text
View/download PDF

173. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance

Author

Huang, Chung-Feng, primary, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Lin, Yu-Ju, additional, Tsai, Pei-Chien, additional, Lin, Zu-Yau, additional, Chan, Soa-Yu, additional, Chen, Shinn-Cherng, additional, Yang, Hwai-I, additional, Huang, Jee-Fu, additional, Lu, Sheng-Nan, additional, Dai, Chia-Yen, additional, Jen, Chin-Lan, additional, Yuan, Yong, additional, L’Italien, Gilbert, additional, Wang, Li-Yu, additional, Lee, Mei-Hsuan, additional, Yu, Ming-Lung, additional, Chuang, Wan-Long, additional, and Chen, Chien-Jen, additional

Published
2017
Full Text
View/download PDF

178. Stratification of hepatocellular carcinoma risk through modified FIB‐4 index in chronic hepatitis B patients on entecavir therapy.

Author

Wang, Hung‐Wei, Su, Wen‐Pang, Lin, Chia‐Hsin, Chuang, Po‐Heng, Lai, Hsueh‐Chou, Peng, Cheng‐Yuan, Hu, Tsung‐Hui, Lu, Sheng‐Nan, Hung, Chao‐Hung, Wang, Jing‐Houng, Chen, Chien‐Hung, and Lee, Mei‐Hsuan

Subjects
CHRONIC hepatitis B, HEPATOCELLULAR carcinoma, REGRESSION analysis, DIABETES, CONFIDENCE intervals, FIBROSIS
Abstract

Background and Aim: Noninvasive fibrosis indices can predict the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). Modified FIB‐4 (mFIB‐4) is a promising noninvasive index for predicting liver fibrosis. To investigate the predictive accuracy of several extant noninvasive fibrosis indices, including mFIB‐4, for HCC incidence in CHB patients receiving long‐term entecavir therapy. Methods: We enrolled 1325 nucleos(t)ide analogue‐naïve CHB patients (noncirrhotic 844; cirrhotic 481) treated with entecavir. Baseline clinical features and fibrosis indices were collected and evaluated for predicting HCC risk through univariate and multivariate Cox regression analyses. Results: Of the 1325 patients, 105 (7.9%) developed HCC during a median follow‐up period of 4.1 years. Age (hazard ratio [HR], 1.039; 95% confidence interval [CI], 1.020–1.059; P < 0.0001), diabetes mellitus (DM) (HR, 1.902; 95% CI, 1.185–3.052; P = 0.0077), and mFIB‐4 (HR, 4.619; 95% CI, 1.810–11.789; P = 0.0014) were independent predictors of HCC in all patients (mFIB‐4 ≥ 1.5 for the noncirrhotic cohort; DM and mFIB‐4 ≥ 2.0 for the cirrhotic cohort). A combination of mFIB‐4 and the DM status stratified the cumulative risk of HCC into three subgroups in all patients (high: mFIB‐4 ≥ 1.5/DM; intermediate: mFIB‐4 ≥ 1.5/non‐DM; and low: mFIB‐4 < 1.5, P < 0.0001) and in the cirrhotic cohort (high: mFIB‐4 ≥ 2.0/DM; intermediate: mFIB‐4 ≥ 2.0/non‐DM; and low: mFIB‐4 < 2.0, P = 0.0007). An mFIB‐4 cutoff value of 1.5 stratified the cumulative risk of HCC in the noncirrhotic cohort (P = 0.015). Conclusions: The mFIB‐4 index alone or in combination with DM is the optimal noninvasive predictor of HCC risk in CHB patients receiving entecavir therapy. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

179. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.

Author

Nguyen, Mindie H, Yang, Hwai-I, Le, An, Henry, Linda, Nguyen, Nghia, Lee, Mei-Hsuan, Zhang, Jian, Wong, Christopher, Wong, Clifford, and Trinh, Huy

Subjects
LIVER cancer patients, CHRONIC hepatitis B, CIRRHOSIS of the liver, TENOFOVIR, VIRAL antigens
Abstract

Background: The effect of newer oral anti-hepatitis B virus (HBV) medication, tenofovir disoproxil (TDF), on liver-related outcomes among Asians is limited. We examined the effect of TDF on the incidence of hepatocellular carcinoma (HCC) in an Asian population with chronic hepatitis B (CHB).Methods: This was a retrospective cohort study of 6914 adults with chronic HBV monoinfection and no history of transplantation who were recruited from 6 US referral, community medical centers and a community based Taiwan cohort for a total of 774 patients who received TDF and 6140 who were not treated. Propensity score matching (PSM) for age, sex, HBV e antigen status, HBV DNA level, alanine aminotransferase (ALT) level, baseline cirrhosis status, and follow-up time was performed to balance the groups, resulting in 591 treated individuals and 591 untreated individuals. Kaplan-Meier analysis was used to estimate the cumulative risk of HCC. Cox proportional hazards models were run to estimate the HCC risk between groups.Results: The 8-year cumulative HCC incidence was significantly higher in the PSM untreated group (20.13% vs 4.69%; P < .0001). Cirrhosis was a significant predictor for HCC (adjusted hazard ratio [aHR], 5.36; 95% confidence interval [CI], 2.73-10.51; P < .001). On multivariate analysis adjusted for age, sex, HBV DNA level, ALT level, and study site, TDF was associated with a 77% reduction in the risk of HCC (aHR, 0.23; 95% CI, .56-.92) in patients with cirrhosis and a 73% reduction (aHR, 0.27; 95% CI, .07-.98) in patients without cirrhosis.Conclusions: Among cirrhotic and noncirrhotic Asian patients with CHB, TDF therapy was significantly associated with a reduction in the 8-year HCC cumulative incidence rate. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

180. Epidemiology and natural history of hepatitis C virus infection

Author

Lee, Mei-Hsuan, Yang, Hwai-I, Yuan, Yong, L’Italien, Gilbert, and Chen, Chien-Jen

Subjects
Adult, Aged, 80 and over, Liver Cirrhosis, Male, Carcinoma, Hepatocellular, Time Factors, Incidence, Liver Neoplasms, Age Factors, Taiwan, virus diseases, Hepacivirus, Middle Aged, Viral Load, Prognosis, Hepatitis C, digestive system diseases, Sex Factors, Risk Factors, Disease Progression, Prevalence, Humans, Female, Topic Highlight, Aged
Abstract

Hepatitis C virus (HCV) affects 130-210 million people worldwide and is one of the major risk factors for hepatocellular carcinoma. Globally, at least one third of hepatocellular carcinoma cases are attributed to HCV infection, and 350000 people died from HCV related diseases per year. There is a great geographical variation of HCV infection globally, with risk factors for the HCV infection differing in various countries. The progression of chronic hepatitis C to end-stage liver disease also varies in different study populations. A long-term follow-up cohort enrolling participants with asymptomatic HCV infection is essential for elucidating the natural history of HCV-caused hepatocellular carcinoma, and for exploring potential seromarkers that have high predictability for risk of hepatocellular carcinoma. However, prospective cohorts comprising individuals with HCV infection are still uncommon. The risk evaluation of viral load elevation and associated liver disease/cancer in HCV (REVEAL-HCV) study has followed a cohort of 1095 residents seropositive for antibodies against hepatitis C virus living in seven townships in Taiwan for more than fifteen years. Most of them have acquired HCV infection through iatrogenic transmission routes. As the participants in the REVEAL-HCV study rarely receive antiviral therapies, it provides a unique opportunity to study the natural history of chronic HCV infection. In this review, the prevalence, risk factors and natural history of HCV infection are comprehensively reviewed. The study cohort, data collection, and findings on liver disease progression of the REVEAL-HCV study are described.

Published
2014

184. Tu1675 Development and Validation of a Risk Score System Inclusive of Antiviral Therapy for Predicting Liver Cirrhosis Risk in Diverse Patients With Chronic Hepatitis B Infection

Author

Jin, Mingjuan, primary, Yang, Hwai-I, additional, Le, An K., additional, Lee, Mei-Hsuan, additional, Hoang, Joseph, additional, Nguyen, Nghia, additional, Lin, Derek, additional, Trinh, Huy N., additional, Li, Jiayi, additional, Zhang, Jian, additional, Chen, Chien-Jen, additional, and Nguyen, Mindie H., additional

Published
2016
Full Text
View/download PDF

185. 420 Higher Risk of Hepatocellular Carcinoma (HCC) in Asian Patients With Chronic Hepatitis C (CHC) With Hepatitis C Virus Genotype 6 (HCV-6) Compared to Asians With Other HCV Genotypes

Author

Hsiao, Tiffany I., primary, Subramaniam, Shreenidhi R., additional, Le, An K., additional, Vu, Vinh D., additional, Trinh, Huy N., additional, Zhang, Jian, additional, Jin, Mingjuan, additional, Lee, Mei-Hsuan, additional, Wong, Vincent, additional, Wong, Grace, additional, and Nguyen, Mindie H., additional

Published
2016
Full Text
View/download PDF

187. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis

Author

Yang, Hwai-I, primary, Tseng, Tai-Chung, additional, Liu, Jessica, additional, Lee, Mei-Hsuan, additional, Liu, Chun-Jen, additional, Su, Tung-Hung, additional, Batrla-Utermann, Richard, additional, Chan, Henry Lik-Yuen, additional, Kao, Jia-Horng, additional, and Chen, Chien-Jen, additional

Published
2016
Full Text
View/download PDF

191. The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B

Author

Hu, Hui-Han, primary, Liu, Jessica, additional, Lin, Yu-Ling, additional, Luo, Wun-Sheng, additional, Chu, Yu-Ju, additional, Chang, Chia-Lin, additional, Jen, Chin-Lan, additional, Lee, Mei-Hsuan, additional, Lu, Sheng-Nan, additional, Wang, Li-Yu, additional, You, San-Lin, additional, Yang, Hwai-I, additional, and Chen, Chien-Jen, additional

Published
2015
Full Text
View/download PDF

194. Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment.

Author

Chen, Ming-Han, Lee, Mei-Hsuan, Liao, Hsien-Tzung, Chen, Wei-Sheng, Lai, Chien-Chih, and Tsai, Chang-Youh

Subjects
*QUALITY of life, *RHEUMATOID arthritis, *ANKYLOSING spondylitis, *CARTILAGE, *BACKACHE
Abstract

Treatment with biological disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatoid arthritis (RA) and ankylosing spondylitis (AS) is popular. The aim of this study was to investigate changes in the quality of life (QoL) in patients after receiving, tapering, or stopping bDMARD treatment. Three hundred and thirty patients with RA and 120 patients with AS were enrolled. Data on the patients receiving bDMARDs were obtained by self-completed questionnaires including the short-form 36 (SF-36) and Global Quality of Life (GQL) scale. A relapse was defined as the QoL becoming worse than that before bDMARD treatment. Significant improvement in all domains of the SF-36 and GQL was noted in the patients after receiving bDMARDs. Improvement in SF-36 was significantly greater in RA patients with a shorter disease duration (< 6 years) and milder patient-assessed disease activity and in AS patients with a shorter disease duration and younger age. There were significant decreases in all domains of the SF-36 and GQL in both groups after reducing/discontinuing bDMARD treatment. The patients in both groups with a shorter period of bDMARD treatment (≤ 3 years) had significantly worse SF-36 scores compared to those with a longer period of bDMARD treatment (> 3 years). The relapse rate after reducing/discontinuing treatment was over 90.0% in the RA patients and over 50.0% in the AS patients within 12 months. bDMARDs significantly improved the QoL of the patients with RA and AS. However, interrupting or stopping the treatment protocol worsened the QoL and led to relapses, especially in the patients who used bDMARDs for a shorter period. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

195. Validation of the albumin‐bilirubin grade‐based integrated model as a predictor for sorafenib‐failed hepatocellular carcinoma.

Author

Li, Chung‐Pin, Su, Chien‐Wei, Hou, Ming‐Chih, Lee, Fa‐Yauh, Lin, Han‐Chieh, Lee, Pei‐Chang, Huang, Yi‐Hsiang, Huo, Teh‐Ia, Chen, Yi‐Tzen, Chao, Yee, and Lee, Mei‐Hsuan

Subjects
LIVER cancer, ALBUMINS, BILIRUBIN, SORAFENIB, PATIENT selection, LIVER metastasis, PROGRESSION-free survival
Abstract

Abstract: Background & Aims: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) but is challenging after treatment failure. Appropriate criteria for enrolling patients into second‐line trials are still limited. In this study, we aimed to establish more objective criteria based on Albumin‐Bilirubin (ALBI) grade to select patients with better post‐progression survival (PPS) for second‐line treatment. Methods: Consecutive 404 advanced HCC patients receiving sorafenib were retrospectively enrolled. All patients were in Child‐Pugh class A and BCLC stage C with either portal vein invasion or extrahepatic metastasis at the beginning of sorafenib treatment. Radiological evaluation based on mRECIST criteria and clinical assessments with compliance were performed on schedule. Results: During the median follow‐up period of 5.8 months, 310 patients developed progressive disease (PD) and 350 deaths occurred. The PD patients were randomized into derivation and validation cohorts by a 1:1 ratio. The independent predictors of poor PPS in derivation cohort were ALBI grade 3 at PD (hazard ratio [HR]=3.24, P = .002), new extrahepatic lesions (NEH) (HR=1.75, P = .011), and early PD within 4 months (HR=1.88, P = .037). ALBI‐PD criteria were proposed by incorporating these three risk factors. In the validation cohort, PPS could be independently predicted by presence of early PD, NEH as well as ALBI grade 3 at PD. Patients within ALBI‐PD criteria had significant longer median PPS than those beyond it even in Child‐Pugh A (9.7 vs 4.9 months, P = .005) subpopulations. Conclusions: The ALBI‐PD criteria can differentiate PPS and stratify the patients with advanced HCC for the second‐line trials or salvage therapy. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

196. Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome‐wide association study.

Author

Lee, Mei‐Hsuan, Huang, Yu‐Han, Chen, Hsuan‐Yu, Khor, Seik‐Soon, Chang, Ya‐Hsuan, Lin, Yu‐Ju, Jen, Chin‐Lan, Lu, Sheng‐Nan, Yang, Hwai‐I, Nishida, Nao, Sugiyama, Masaya, Mizokami, Masashi, Yuan, Yong, L'Italien, Gibert, Tokunaga, Katsushi, Chen, Chien‐Jen, and for the REVEAL‐HCV Cohort Study Group

Published
2018
Full Text
View/download PDF

197. Influence of Nonalcoholic Fatty Liver Disease With Increased Liver Enzyme Levels on the Risk of Cirrhosis and Hepatocellular Carcinoma.

Author

Huang, Yu-Han, Chan, Chi, Lee, Hye-Won, Huang, Claire, Chen, Yen-Ju, Liu, Po-Chun, Lu, Sheng-Nan, Chuang, Wan-Long, Huang, Jee-Fu, Yu, Ming-Lung, Koshiol, Jill, and Lee, Mei-Hsuan

Abstract

The influence of nonalcoholic fatty liver disease (NAFLD) on the long-term risk of cirrhosis and hepatocellular carcinoma (HCC) in Asian populations has not been widely investigated. We enrolled 129,374 adults aged 30 years and older, all of whom participated in a health screening program from 2008 through 2013, were seronegative for hepatitis B surface antigen and anti–hepatitis C virus antibodies, and had limited daily alcohol consumption (<20 g/d for men and <10 g/d for women). Abdominal ultrasonography was performed to determine the presence of NAFLD. The participants were divided into the following groups: NAFLD with increased or normal liver enzyme levels, and non-NAFLD with normal liver enzyme levels. The incidences of cirrhosis and HCC were determined through computerized data linkage with nationwide registries. Cox proportional hazard models were used to estimate the hazard ratios of NAFLD on the risks of cirrhosis and HCC. The incidence rates of cirrhosis and HCC increased as follows: non-NAFLD with normal liver enzyme levels (n = 66,801; 51%), NAFLD with normal liver enzyme levels (n = 41,461; 32%), and NAFLD with increased liver enzyme levels (n = 21,112; 16%). In the NAFLD group with increased liver enzyme levels and the NAFLD group with normal liver enzyme levels, the corresponding multivariate-adjusted hazard ratios for cirrhosis were 3.51 (95% confidence interval [CI]: 2.36–5.22) and 0.73 (95% CI: 0.46–1.16), and for HCC were 1.91 (95% CI: 1.08–3.38) and 0.57 (95% CI: 0.31–1.04), respectively, compared with the non-NAFLD group (P for trend <.001). The findings were consistent after restricting the analysis to nonobese individuals (body mass index, <25 kg/m2) and nonobese individuals without diabetes (P <.05). Individuals with NAFLD and increased liver enzyme levels showed significantly higher risks for cirrhosis and HCC and should be monitored. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

198. R331W Missense Mutation of Oncogene YAP1 Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability

Author

Chen, Hsuan-Yu, primary, Yu, Sung-Liang, additional, Ho, Bing-Ching, additional, Su, Kang-Yi, additional, Hsu, Yi-Chiung, additional, Chang, Chi-Sheng, additional, Li, Yu-Cheng, additional, Yang, Shi-Yi, additional, Hsu, Pin-Yen, additional, Ho, Hao, additional, Chang, Ya-Hsuan, additional, Chen, Chih-Yi, additional, Yang, Hwai-I, additional, Hsu, Chung-Ping, additional, Yang, Tsung-Ying, additional, Chen, Kun-Chieh, additional, Hsu, Kuo-Hsuan, additional, Tseng, Jeng-Sen, additional, Hsia, Jiun-Yi, additional, Chuang, Cheng-Yen, additional, Yuan, Shinsheng, additional, Lee, Mei-Hsuan, additional, Liu, Chia-Hsin, additional, Wu, Guan-I, additional, Hsiung, Chao A., additional, Chen, Yuh-Min, additional, Wang, Chih-Liang, additional, Huang, Ming-Shyan, additional, Yu, Chong-Jen, additional, Chen, Kuan-Yu, additional, Tsai, Ying-Huang, additional, Su, Wu-Chou, additional, Chen, Huei-Wen, additional, Chen, Jeremy J.W., additional, Chen, Chien-Jen, additional, Chang, Gee-Chen, additional, Yang, Pan-Chyr, additional, and Li, Ker-Chau, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results